Patents Assigned to ISTITUTO EUROPEO DI ONCOLOGIA S.R.L.
-
Patent number: 11918580Abstract: The present disclosure relates to methods of treating cancer and pharmaceutical compositions for use in the treatment of cancer, including LSD1-inhibitor-resistant cancers, comprising administering to a subject an effective amount of a cell cycle inhibitor, such as a CDK4/6 inhibitor or a p21 enhancer, and an effective amount of a LSD1 inhibitor.Type: GrantFiled: April 25, 2018Date of Patent: March 5, 2024Assignees: Istituto Europeo di Oncologia S.r.l., Università degli Studi Di MilanoInventors: Saverio Minucci, Pier Giuseppe Pelicci, Seyed Amir Hosseini
-
Publication number: 20230381291Abstract: The present invention provides antigen presenting cells (APC) carrying human tumor-associated peptides on the cell surface as well as immunogenic compositions including the tumor-associated peptides and/or the antigen presenting cells according to the invention. The immunogenic composition of the invention is useful as a vaccine in the prevention and/or treatment of a tumor disease, particularly melanoma and melanoma residual disease.Type: ApplicationFiled: July 8, 2021Publication date: November 30, 2023Applicants: HUMANITAS MIRASOLE S.P.A., HUMANITAS UNIVERSITY, ISTITUTO EUROPEO DI ONCOLOGIA S.R.L.Inventors: Maria RESCIGNO, Alessia MELACARNE, Giuseppe PENNA
-
Publication number: 20230310421Abstract: The present invention relates to LSD1 inhibitors for use in the treatment and/or prevention of a viral infection caused by and/or associated with RNA viruses, preferably Coronaviridae. The LSD1 inhibitors are able to inhibit or prevent the viral induced increased expression of inflammatory cytokines while sparing the expression of Interferon and Interferon-Stimulated Genes. The present invention further concerns a combination and a pharmaceutical composition including the molecules or combinations thereof.Type: ApplicationFiled: April 14, 2021Publication date: October 5, 2023Applicants: ISTITUTO EUROPEO DI ONCOLOGIA S.R.L., UNIVERSITA' DEGLI STUDI DI MILANOInventors: Piergiuseppe PELICCI, Saverio MINUCCI, Fabio SANTORO, Mauro ROMANENGHI, Luca MAZZARELLA, Paul-Edward MASSA, Bruno ACHUTTI DUSO
-
Publication number: 20220339163Abstract: The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising compounds of formula (I), to their medical use and to their process of preparation.Type: ApplicationFiled: June 3, 2020Publication date: October 27, 2022Applicants: IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE, IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L.Inventors: Sebastiano PASQUALATO, Maurizio PASI, Raffaella AMICI, Mario VARASI, Ciro MERCURIO, Luca SARTORI, Simona POLO, Elena MASPERO, Giovanni FAGA'
-
Patent number: 11441191Abstract: The present invention relates to refined prognostic clinical tools, methods, and kits for the evaluation of risk and treatment of distant recurrence in ER+/HER2? breast cancer patients.Type: GrantFiled: June 19, 2017Date of Patent: September 13, 2022Assignees: Istituto Europeo di Oncologia S.r.l., Fondazione Istituto Firc di Oncologia Molecolare (IFOM), University of MilanInventors: Pier Paolo Di Fiore, Salvatore Pece, Manuela Vecchi, Stefano Confalonieri
-
Publication number: 20210155709Abstract: The present disclosure refers to a method for identifying an immunoglobulin, recombinant or synthetic antigen-binding fragments thereof that present in vivo tumor binding activity and do not significantly cross-react with normal cells and to antibodies thereby obtained and to medical uses thereofType: ApplicationFiled: June 19, 2019Publication date: May 27, 2021Applicant: IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L.Inventors: Luisa LANFRANCONE, Paul Edward MASSA, Massimiliano MAZZA, Pier Giuseppe PELICCI
-
Patent number: 10980777Abstract: The present application relates to compounds of formula (I), wherein A, R, R1, and R2 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy.Type: GrantFiled: August 17, 2018Date of Patent: April 20, 2021Assignee: Istituto Europeo di Oncologia S.r.l.Inventors: Mario Varasi, Anna Cappa, Paola Vianello, Loris Moretti, Luca Sartori, Ciro Mercurio
-
Patent number: 10961255Abstract: The present invention relates to imidazole derivatives, wherein A, R, R1, and R2 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy.Type: GrantFiled: December 20, 2019Date of Patent: March 30, 2021Assignee: Istituto Europeo di Oncologia S.r.l.Inventors: Paola Vianello, Alessia Romussi, Anna Cappa, Paolo Trifiro′, Mario Varasi, Luca Sartori, Ciro Mercurio
-
Publication number: 20200164047Abstract: The present invention relates to at least one modulator of PP2A or at least one modulator of PP2A-like phosphatase or at least one modulator of PP2A and PP2A-like phosphatase or a combination of said modulators for use in the treatment of a disease characterized by an alteration in the DNA damage response. The present invention also relates to a method to identify a subject to be treated with a PP2A modulator comprising detecting in the genome of said patient a mutation in PP2A.Type: ApplicationFiled: May 21, 2018Publication date: May 28, 2020Applicants: UNIVERSITÀ DEGLI STUDI DI MILANO, ISTITUTO EUROPEO DI ONCOLOGIA S.R.L., IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLAREInventors: Saverio MINUCCI, Mohamed ELGENDY, Riccardo CAZZOLI, Sebastiano PERI, Elisa FERRARI, Marco FOIANI
-
Patent number: 10562914Abstract: The present invention relates to imidazole derivatives of Formula (I), wherein A, R, R1, and R2 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy.Type: GrantFiled: May 18, 2017Date of Patent: February 18, 2020Assignee: Istituto Europeo di Oncologia S.r.l.Inventors: Paola Vianello, Alessia Romussi, Anna Cappa, Paolo Trifiro', Mario Varasi, Luca Sartori, Ciro Mercurio
-
Publication number: 20190175670Abstract: The invention refers to a composition comprising a fermented product of Lactobacillus casei or paracasei species, preferably for use in the treatment of eye inflammation syndromes and to a method for obtaining the same.Type: ApplicationFiled: August 3, 2017Publication date: June 13, 2019Applicant: ISTITUTO EUROPEO DI ONCOLOGIA S.R.L.Inventors: Maria RESCIGNO, Giuseppe PENNA
-
Patent number: 10233165Abstract: The present disclosure relates to cyclopropyl compounds of general formula (I), wherein R1, and R2 are as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy.Type: GrantFiled: May 29, 2015Date of Patent: March 19, 2019Assignee: Istituto Europeo di Oncologia S.r.l.Inventors: Paola Vianello, Mario Varasi, Ciro Mercurio, Anna Cappa, Giuseppe Meroni, Manuela Villa, Antonello Mai, Sergio Valente
-
Patent number: 10183952Abstract: The present application relates to thienopyrrole derivatives, compounds of Formulas (I) and (Ia), wherein R, R1, R2 and R3 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. The compounds of the application can be useful for inhibiting KDM1 and the prevention and/or treatment of cancer, infectious disease, or a disease characterized by aberration of cellular energy metabolism, e.g., obesity.Type: GrantFiled: September 4, 2015Date of Patent: January 22, 2019Assignee: Istituto Europeo di Oncologia S.r.l.Inventors: Paola Vianello, Luca Sartori, Mario Varasi, Ciro Mercurio, Elisa Zagarri, Anna Cappa, Alessia Romussi, Manuela Villa, Giuseppe Meroni, Loris Moretti
-
Patent number: 9944589Abstract: The present invention relates to cyclopropyl derivatives of general formula (I), wherein A, R1, and R2 are as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy.Type: GrantFiled: December 3, 2013Date of Patent: April 17, 2018Assignee: Istituto Europeo di Oncologia S.r.l.Inventors: Mario Varasi, Paola Vianello, Florian Thaler, Paolo Trifiro′, Ciro Mercurio, Giuseppe Meroni
-
Publication number: 20150057159Abstract: A diagnostic and/or prognostic model of at least 5 serum miRNAs selected among a group of 34 miRNAs that identifies subjects with early stage lung cancer, namely non-small cell lung carcinomas (NSCLCs), in a population of asymptomatic high-risk individuals, with 80% accuracy. The model could also distinguish between benign and malignant lesions and is sensitive enough to capture the disease onset. In addition, the model could also diagnose or confirm a diagnosis of lung cancer in symptomatic patients, and monitor the lung tumor status after treatment with surgery and/or chemotherapy and/or radiotherapy in a subject with such lung cancer.Type: ApplicationFiled: December 22, 2011Publication date: February 26, 2015Applicants: ISTITUTO EUROPEO DI ONCOLOGIA S.R.L., UNIVERSITA DEGLI STUDI DI MILANO, IFOM Fondazione Istituto FIRC di Oncologia Moleco lareInventors: Pierpaolo Di Fiore, Fabrizio Bianchi, Matteo Jacopo Luca Nicolò Marzi, Francesco Nicassio
-
Publication number: 20130330276Abstract: A conjugate of human albumin (HA) and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA) insoluble in aqueous medium at a pH of 3-8.5 and whose IR spectrum shows an absorption at about 700 cm?1 is described; a complex is further described consisting of a conjugate of HA and p-SCN-Bn-DOTA (HAC) according to claim 1 or 2 and a radioactive isotope of an element selected among the group consisting of P, Sr, Rh, Pd, I, Sm, Er, Au, At Bi, In, Lu, Y, Re, Cu and Ag, as well as procedures for preparing said conjugate and said complex as well as the use of such conjugate in the identification of mammalian neoplastic lesions by the R.O.L.L. methodology (“Radioguided Occult Lesion Localization”).Type: ApplicationFiled: December 23, 2011Publication date: December 12, 2013Applicants: ISTITUTO EUROPEO DI ONCOLOGIA S.R.L., UNIVERSITÀ DEGLI STUDI DI GENOVAInventors: Gabriele Caviglioli, Brunella Parodi, Sergio Cafaggi, Eleonora Russo, Paola Cirrincione, Marco Chinol, Giovanni Paganelli
-
Publication number: 20130129713Abstract: It is disclosed a method for obtaining a specific tumor antigen peptide repertoire loaded and/or activated dendritic cell comprising the steps of: a) exposing in suitable conditions a tumor cell expressing said specific tumor antigen peptide repertoire to at least one Pattern Recognition Receptor (PRR) agonist and/or to an inflammatory cytokine to obtain a tumor cell with an increased activity of at least one protein belonging to the group of connexins; b) co-culturing said tumor cell with an increased activity of at least one protein belonging to the group of connexins with dendritic cells, to get specific tumor antigen peptide repertoire loaded and/or activated dendritic cells; Step a) and b) are performed simultaneously or in sequence. The group of connexins preferably consists of connexin 43, connexin 40, connexin 45, connexin 47, connexin 50.Type: ApplicationFiled: August 4, 2011Publication date: May 23, 2013Applicant: IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L.Inventors: Maria Rescigno, Fabiana Saccheri